Protocol Ledger

NCT04681131 · Phase II · COMPLETED

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Interventional Phase II clinical trial protocol NCT04681131 sponsored by BioAtla in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-17 Enrollment: 85 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04681131
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)85 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04681131
Protocol FieldVerified Registry Value
NCT IdentifierNCT04681131
Consolidated Lead SponsorBioAtla
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment85 participants (ACTUAL)
Registered Start Date2021-03-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI